FR 78844
FR 78844 is an orally active bone resorption inhibitor. FR 78844 attenuates metaphyseal bone mineral density decreases in Streptozotocin (HY-13753)-induced diabetic rats, and Heparin (HY-17567A)-induced osteopenia, but does not affect vitamin D-deficient rat bone loss. FR 78844 can be used for the research of osteopenia.
For research use only. We do not sell to patients.
- CAS No.: 112856-39-0
- Formula: C8H9NNa2O6P2S
- Molecular Weight:355.15
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
FR 78844 potently inhibits PTH-induced calcium release from rat calvaria in vitro with an IC50 of 4.4 × 10-7 M[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) significantly attenuates ovariectomy-induced osteopenic bone loss in rats[1].
FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) does not attenuate vitamin D deficiency-induced osteopenic bone loss in rats[1].
FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) dose-dependently attenuates Heparin-induced osteopenia in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (9-week-old female; Streptozotocin (STZ)-induced diabetic model)[1]
-
Dosage:1; 10; 100 mg/kg
-
Administration:p.o.; 5 days a week; 4 weeks
-
Result:Attenuated the decrease in femur metaphyseal bone mineral density by 66% at 100 mg/kg dose compared to vehicle-treated STZ rats.
Did not produce a significant effect at 1 mg/kg and 10 mg/kg doses.
-
Animal Model:Wistar rats (9-week-old female; ovariectomized model)[1]
-
Dosage:1; 10; 100 mg/kg
-
Administration:p.o.; 5 days a week; 4 weeks
-
Result:Attenuated the decrease in femur metaphyseal bone mineral density by 81% at 100 mg/kg dose compared to vehicle-treated ovariectomized rats.
Did not produce a significant effect at 1 mg/kg and 10 mg/kg doses.
-
Animal Model:Wistar rats (4-week-old female; vitamin D-deficient model)[1]
-
Dosage:1; 10; 100 mg/kg
-
Administration:p.o.; 5 days a week; 4 weeks
-
Result:Did not produce a significant effect on femur metaphyseal bone mineral density at any tested dose compared to vehicle-treated vitamin D-deficient rats.
-
Animal Model:Wistar rats (female, 9 weeks old, osteopenia induced by Heparin sodium 2000 U/kg·day subcutaneously 5 days a week for 4 weeks)[2]
-
Dosage:1; 10; 100 mg/kg
-
Administration:p.o.; 5 days a week; 4 weeks
-
Result:Attenuated the heparin-induced decrease in metaphyseal bone mineral density in a dose-dependent manner.
Produced a significant increase in metaphyseal bone mineral density at 100 mg/kg compared to the vehicle-treated heparinized group.
Showed a significant improvement in metaphyseal bone mineral density at 10 mg/kg relative to the vehicle group.
Chemical Information
-
CAS No. 112856-39-0
-
Molecular Weight 355.15
-
Formula C8H9NNa2O6P2S
-
SMILES
S=C(NC1=CC=CC=C1)C(P(O)(O)=O)P(O[Na])(O[Na])=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Takeshita N, et al. Possible involvement of vitamin D3-deficiency and relatively enhanced bone resorption in the development of bone loss in streptozotocin-induced diabetic rats. Life Sci. 1994;55(4):291-9. [Content Brief]
[2]. Mutoh S, et al. Characterization of heparin-induced osteopenia in rats. Endocrinology. 1993 Dec;133(6):2743-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FR 78844 Related Classifications
HY-122075 Related Classifications
Powered by Bioz